Effect of Different SARS-CoV-2 Vaccine Schedules & Vaccination Intervals

Status Completed

Clinical Trial Summary

Investigation of the reactogenicity and immunogenicity of homologous and heterologous vaccine combinations with regard to the formation of SARS-CoV-2 antispike antibodies in health care workers after basic immunization and boost vaccination

Clinical Trial Description

The basic immunizations (first and second vaccination) were performed from January to June 2021 using the m-RNA vaccine BNT162b2 (BioNTech/Pfizer, B)9 and the vector-based vaccine ChAdOx1-S (AstraZeneca, A). BNT162b2 was used to boost vaccine all study population. The time interval between the basic immunisation and the boost vaccination varied. Four vaccine-groups could be distinguished: Group 1 received BNT162b2 with the second vaccination 3 weeks after the first vaccination. Vaccinees of groups 2 and 3 received AZD1222/ChAdOx1-S as first vaccination and could choose after 12 weeks whether second vaccination with BNT162b2 or AZD1222/ChAdOx1-S should be carried out. This results in homologous (first: AZD1222/ChAdOx1-S, second: AZD1222/ChAdOx1-S) and heterologous (first: AZD1222/ChAdOx1-S, second: BNT162b2) vaccine combinations. Group 4 received BNT162b2 with the second vaccination 6 weeks after first vaccination. Blood samples were collected at six time points: four weeks, three and six months after completion of the basic immunization, immediately before boost vaccination, four weeks and three months after boost vaccination. Reactogenicity after first, second, and boost vaccination was assessed using questionnaires to determine vaccine-induced adverse drug reactions (ADR) within seven days after the respective vaccinations. In addition, demographic data (age, gender, occupational group, allergies) were collected, local and systemic vaccination reactions are differentiated and the need for medication and inability to work as a result of vaccination reactions are prospectively recorded. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05076227
Study type	Observational
Source	University of Witten/Herdecke
Contact
Status	Completed
Phase
Start date	January 30, 2021
Completion date	March 27, 2022

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04979858` - Reducing Spread of COVID-19 in a University Community Setting: Role of a Low-Cost Reusable Form-Fitting Fabric Mask	N/A
Recruiting	`NCT05311410` - Viral Kinetics of SARS-CoV-2 in Patients With COVID-19 in the Intensive Care Unit Undergoing Dental Procedures	N/A
Active, not recruiting	`NCT05073718` - SARS-CoV-2 and Acetylsalicylic Acid (SARA)	Phase 3
Completed	`NCT05055505` - The School SPIT Study - Elementary Schools in Low COVID-19 Incidence Regions	N/A
Completed	`NCT05055492` - The School SPIT Study - Elementary Schools in High COVID-19 Incidence Regions	N/A
Completed	`NCT05060510` - The School SPIT Study - COVID-19 Testing in Secondary Schools	N/A
Completed	`NCT05054218` - COVID-19 Immunogenicity of a Third Dose of mRNA-1273 Vaccine Among Cancer Patients
Completed	`NCT05449392` - Topical Antibacterial Agents for Prevention of COVID-19	Phase 1
Completed	`NCT05076253` - Efficacy of Ivermectin in COVID-19	Phase 1/Phase 2
Recruiting	`NCT05172024` - Understanding the Long-term Impact of COVID-19 in Adults (RECOVER)
Terminated	`NCT05593770` - International Sites: Novel Experimental COVID-19 Therapies Affecting Host Response	Phase 2/Phase 3
Completed	`NCT05030974` - RECOVAC Repeated Vaccination Study	Phase 4
Withdrawn	`NCT05067946` - Evaluation of Efficacy, Safety and Immunogenicity of GX-19N in Healthy Individuals Who Have Received COVID-19 Vaccines	Phase 2/Phase 3
Not yet recruiting	`NCT05013034` - Exploratory Regimen of Basiliximab for Treatment of Pulmonary Cytokine Storm in SARS-CoV-2 Hospitalized Adult Patients	Phase 2
Withdrawn	`NCT05393999` - SABRE: A Single-arm Prospective Study Measuring Safety and Tolerability of SARS-CoV-2 Neutralising Antibodies in High-risk Populations	Phase 2
Recruiting	`NCT05047783` - Masitinib in Patients With Symptomatic Mild to Moderate COVID-19	Phase 2
Not yet recruiting	`NCT05116657` - Obstructive Sleep Apnoea Post Covid 19: Role of the Upper Airway Microbiome
Recruiting	`NCT04590222` - Impact of a Monoamine Oxidase Inhibitor on the Phenotype of Blood Mononucleated Cells in Patients With COVID-19
Completed	`NCT04551911` - Safety and Efficacy of Rayaldee for Treating Mild to Moderate COVID-19	Phase 2
Completed	`NCT04953039` - Use of Saliva for COVID-19 Diagnosis

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Effect of Different SARS-CoV-2 Vaccine Schedules and Vaccination Intervals on Reactogenicity and Humoral Immunogenicity

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms